David M. Erlanger, Ph.D., ABPP/CN, President & Chief Scientific Officer
Dr. Erlanger received his doctorate in psychology from Columbia University and completed training in clinical neuropsychology at the Albert Einstein College of Medicine and the Weill Medical College of Cornell University. He is on the faculties of the Albert Einstein College of Medicine and Columbia University. Over the past six years, Dr. Erlanger developed and led the PanMedix research program in performing extensive research in the area of repeated assessment of cognitive functioning of individuals suffering from CNS illness. In 2002, Dr. Erlanger was responsible for developing the cognitive test protocol for Sention's MCI trial in which C105's pattern of cognitive activation was first identified and described. This new understanding was a key element in determining the focus of future C105 research efforts toward demonstrating efficacy for improving memory function in MS patients with cognitive impairment.

Peter Zarevics, Director of Clinical Operations
Mr. Zarevics is the former Vice President of Clinical Operations at Sention, where he had end-to-end responsibility for implementation of all Sention clinical development programs. During his tenure, he progressed three molecules into human clinical studies within 2 years and progressed C105 into multiple Phase II trials in multiple indications. He was responsible for management of consultants and vendors, and liaison with investigators to ensure achievement of project timelines and deliverables. Prior to Sention, he was Director, Clinical Operations for Stressgen Biotechnologies. He has over thirty years of experience in domestic and international drug development including SmithKline Beecham, Merck, Astra/Merck and industry-leading consulting companies (G.H. Besselaar, now Covance). Mr. Zarevics has participated in 10 NDA/sNDA/MAA submissions in multiple therapeutic areas including CNS.

Frederick E. Munschauer III, MD, Co-Principle Investigator
Dr. Munschauer is the director of the Research Center for Stroke and Heart Disease at Kaleida Health in Buffalo, NY, and his primary research interests are vascular disease prevention, healthcare delivery, and multiple sclerosis. Along with Dr. Benedict, Dr. Munschauer led the initial C105 pilot project to determine the merit of pursuing approval of C105 for treatment of cognitive impairment in MS patients. Dr. Munschauer is involved in a number of clinical trials funded by the National Institutes of Health as well as the pharmaceutical industry. His research has been published in Clinical Therapeutics, Stroke, Neurology, and Annals of Neurology. Dr. Munschauer is an associate professor of clinical neurology and internal medicine at the State University of New York at Buffalo School of Medicine.

Ralph H. B. Benedict, Ph.D., ABPP/CN, Co-Principle Investigator
Dr. Benedict is an associate professor of neurology at the SUNY Buffalo School of Medicine, where he serves as the director of neuropsychology in the Division of Developmental and Behavioral Neurosciences. Along with Dr. Munschauer, Dr. Benedict led the initial C105 pilot project to determine the merit of pursuing approval of C105 for treatment of cognitive impairment in MS patients. Dr. Benedict has published numerous key papers in the field of cognitive impairment in MS and has served on numerous advisory panels in the area. He completed a doctorate in clinical psychology at Arizona State University in 1990, followed by a two-year postdoctoral residency in neuropsychology at the Johns Hopkins University School of Medicine. He has published over 55 tests and peer-reviewed articles in journals that reflect research interests in assessment, schizophrenia, rehabilitation, neuroimaging, and multiple sclerosis. He has published numerous book chapters and abstracts, and he has served as a reviewer for over 20 psychology and medical journals.

Jeff Barth, Ph.D., ABPP/CN, Chief Scientific Advisor
Dr. Barth is Chief of Medical Psychology and John Edward Fowler Professor of Clinical Psychology in the Department of Psychiatric Medicine, University of Virginia School of Medicine. He is also director of the Neuropsychology Assessment Laboratories and a professor at the Institute of Law, Psychiatry and Public Policy. He has served as an investigator or consultant to numerous research grants funded by organizations such as the National Institutes of Health, the Robert Wood Johnson Foundation, and the Pew Foundation. Dr. Barth has been an advisor to PanMedix on development of effective methodologies for pharmaceutical industry research since its founding in 1999 and in that capacity has been involved with research on C105 since 2002. In addition, Dr. Barth obtained first-hand experience with C105 as an investigator for the C105 MCI trial.

Christian L. Oberbeck, Chairman of the Board

Mr. Oberbeck is Managing Director of Saratoga Partners, a New York based private equity investment firm.

Richard A. Petrocelli, Director and Chief Financial Officer